ng the international investment bank, J.P. Morgan & Co. Incorporated. He joined Geron in 1995 as the company's Chief Financial Officer, Treasurer and Secretary and has also served as the company's Vice President of Corporate Development. Mr. Greenwood is a director of two of the company's subsidiaries, Geron Bio-Med Limited and TA Therapeutic Ltd. as well as a director of ViaGen, Inc., an Arizona corporation, and Clone International, an Australian company. Mr. Greenwood serves on the Board of Regents of Pacific Lutheran University from which he holds a Bachelor of Arts. He also has an M.B.A. from Harvard Business School.
Dr. Chaudhuri and Mr. Greenwood join current Corium board members Ron Eastman, Chairman of the Board of Corium and Managing Director at Essex Woodlands Health Ventures, Dr. Phyllis Gardner, Partner at Essex Woodlands and Professor of Medicine at Stanford University, John Kozarich, Chairman and President, ActivX Biosciences, Inc., Robert Thomas, former CEO of FoxHollow Technologies, Daniel G. Welch, CEO and President of InterMune, Peter D. Staple, CEO and President of Corium and Gary W. Cleary, co-founder of Corium. The Company is currently developing and manufacturing a pipeline of advanced transdermal products employing its proprietary MicroCor® microneedle technology and Corplex™ polymer adhesive technology. Essex Woodlands Health Ventures has been the lead investor in Corium since 2007.
Corium is headquartered in Menlo Park, CA, with manufacturing facilities in Grand Rapids, MI.
About Corium International, Inc.
Corium International, Inc. develops and manufactures products based on its advanced transdermal drug delivery technologies. The company has developed and clinically validated two highly differentiated state of the art transdermal technologies: MicroCor® is designed for needle-free delivery of large molecules such as proteins and peptides, and Corplex
Page: 1 2 3 Related medicine technology :1
|SOURCE Corium International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials2
. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig3
. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business4
. Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board5
. Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors6
. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO7
. Encorium Reports Second Quarter 2010 Financial Results8
. Encorium Group, Inc. Announces Terms of Proposed Rights Offering9
. Encorium Group, Inc. Provides Update on Its Previously Announced Rights Offering10
. Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering11
. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference